UBE2N

Across TCGA pan-cancer cohorts, UBE2N RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated UBE2N data layer compared with 3 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher UBE2N RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBE2N expression acts as an unfavorable survival marker, although some lineages such as KIRC and THYM show a favorable association.

LIHC, UVM, and HNSC are the cancer types where UBE2N RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.452	0.626	<.001	83	view →
UVM	DFS	Median	III,IV	0.258	0.805	.001	70	view →
HNSC	OS	Quartile	II,III,IV	0.417	0.767	.001	67	view →
MESO	OS	Median	All	0.420	0.664	<.001	66	view →
ACC	OS	Median	IV	0.295	0.745	.001	51	view →
LUAD	OS	Median	All	0.207	0.436	.005	42	view →
ESCA	OS	Quartile	III,IV	0.352	0.736	.003	32	view →
LGG	OS	Median	All	0.746	0.876	<.001	24	view →
LAML	DFS	Tertile	All	0.374	0.593	.015	22	view →
KIRC	DFS	Median	All	0.731	0.516	.003	19	view →
THYM	OS	Median	All	0.960	0.777	.005	16	view →
SARC	OS	Tertile	All	0.446	0.716	.008	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

UBE2N–LIHC (DFS)

Open the LIHC breakdown →